ArticleThe journal of allergy and clinical immunology. Global2026
Remission in moderate-to-severe pediatric asthma: Definitions, assessment, prevalence, predictors, and outcomes-a scoping review.
Article in The journal of allergy and clinical immunology. Global, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Remission is emerging as a novel therapeutic target in asthma, particularly with the advent of biologic therapies. Although spontaneous remission is recognized in mild childhood asthma, little is known about the concept of remission in children with moderate-to-severe asthma. Objective: This study aimed to synthesize available evidence on definitions, assessment methods, prevalence, predictors, and long-term outcomes of remission in children with moderate-to-severe asthma. Methods: This scoping review followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews guidance. MEDLINE and EMBASE were searched from 2003 onward. Eligible studies included randomized clinical trials and observational studies involving children or adolescents with moderate-to-severe asthma that reported remission or remission-related subdomains. Results: Of 2076 records identified, 8 studies met inclusion criteria (1 trial, 7 observational). Definitions of remission varied substantially and predominantly relied on clinical criteria (absence of symptoms or medication use), with inconsistent incorporation of lung function and none including inflammatory biomarkers. Remission prevalence ranged widely, from 4% to 41.9%, with the highest rates observed in a recent biologic trial; however, assessment periods were highly variable, ranging from 24 weeks to 3 years. Predictors of a lower likelihood of remission included female sex, atopy, and older age at initial diagnosis. Available evidence suggests a persistent risk of subclinical inflammation and relapse despite achieving clinical remission. Conclusions: Evidence on remission in moderate-to-severe pediatric asthma remains limited and heterogeneous, often in the context of ongoing treatment. Standardized, multidomain definitions are urgently needed to inform treat-to-target strategies and future clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.